Adipocytokines and thyreopathies

1. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003; 19: 457–466.

2. Krahulec B. Patogenéza komplikácií obezity. Vnitř Lék 2010; 56: 1050–1052.

3. Fernández-Real JM, Lopey-Bermejo A, Sasamitjana R, et al. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003; 88: 2714–2718.

4. Cabanelas A, Cordeiro A, Santos Almeida NA, et al. Effect of triiodothyronine on adiponectin expression and leptin release by white adipose tissue of normal rats. Horm Metab Res 2010; 42: 254–260.

5. Yaturu S, Prado S, Grimes SR. Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J Cell Biochem 2004; 93: 491–496.

6. Saito T, Kawano T, Saito T, et al. Elevation of serum adiponectin levels in Basedow disease. Metab 2005; 54: 1461–1466.

7. Yu H, Yang Y, Zhang M, et al. Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects. Nutr Metab 2006; 3: 13.

8. Siemińska L, Niedzolka D, Pillich A, et al. Serum concentrations of adiponectin and resistin in hyperthyroid Graves’ disease patients. Eur J Clin Invest 2008; 31: 745–749.

9. Seifi S, Tabandeh MR, Nazifi S, et al. Regulation of adiponectin gene expression in adipose tissue by thyroid hormones. J Physiol Biochem 2012; 68: 193–203.

10. Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: An experimental and clinical update. Endocr Connect 2013; 2: 30–38.

11. Kim BY, Mok JO, Kang SK, et al. The relationship between serum adipocytokines and Graves’ ophtalmopathy. Endocr J 2016; 63: 425–430.

12. Iglesias P, Alvarez Fidalgo P, Codoceao R, et al. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2003; 59: 621–629.

13. Altinova AE, Törüner FB, Bukan N, et al. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clin Endocrinol 2006; 65: 530–535.

14. Kokkinos S, Papayoglou D, Zisimopoulos A, et al. Retinol binding protein-4 and adiponectin levels in thyroid overt and subliclinical dysfunction. Exp Clin Endocrinol Diabetes 2016; 124: 87–92.

15. Nagasaki T, Inaba M, Hiura Y, et al. Plasma levels of adiponectin and soluble thrombomodulin in hypothyroid patients with normal thyroid function following levothyroxine replacement therapy. Biomed Pharmacother 2005; 59: 571–577.

16. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab 2006; 91: 4930–4937.

17. Pontikides N, Loustis K, Koliakos G, et al. Serum cytokines levels in hypothyroidism before and after treatment: relationship with body weight and body composition. Proceedings of the 31st European Thyroid Association Meeting 2006. Naples 144, 197.

18. Iglesias P, Díez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007; 40: 61–70.

19. Siemińska L, Wojciechowska C, Kos-Kudła B, et al. Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto’s thyroiditis. Endokrynol Pol 2010; 61: 112-116.

20. Kaplan O, Uzum AK, Aral H, et al. Unchanged serum adipokine concentrations in the setting of short-term thyroidectomy-induced hypothyroidism. Endocr Pract 2012; 18: 887–893.

21. Yldiz BO, Aksoy DY, Harmanci A, et al. Effects of l-thyroxine therapy on circulating leptin and adiponectin levels in subclinical hypothyroidism: a prospective study. Arch Med Res 2013; 44: 317–320.

22. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. Eur J Clin Invest 2011; 41: 1202-1209.

23. Ozcelik F, Yuksel C, Arslan E, et al. Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatosteatosis and insulin resistance. Arch Med Res 2013; 44: 273–280.

24. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000; 74: 34–41.

25. O’Carroll AM, Selby TL, Palkovits M, et al. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 2000; 1492: 72–80.

26. Scott IC, Masri B, D’Amico LA, et al. The g protein-coupled receptor agtrl1b regulates early development of myocardial progenitors. Dev Cell 2007; 12: 403–413.

27. Zeng XX, Wilm TP, Sepich DS, et al. Apelin and its receptor control heart field formation during zebrafish gastrulation. Dev Cell 2007; 12: 391–402.

28. Xie H, Tang SY, Cui RR, et al. Apelin and its receptor are expressed in human osteoblasts. Regul Pept 2006; 134: 118–125.

29. Principe A, Melgar-Lesmes P, Fernández-Varo G, et al. The hepatic apelin system: A new therapeutic target for liver disease. Hepatology 2008; 48: 1193–1201.

30. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764–1771.

31. Kechyn S, Barnes G, Howard L. Assessing dynamic changes in plasma apelin concentration in response to maximal exercise in man. Eur Respir J 2015; 46: PA2316.

32. Lambrecht NW, Yakubov I, Zer C, et al. Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion. Physiol Genomics 2006; 25: 153–165.

33. Sörhede Winzell M, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005; 131: 12–17.

34. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764–1771.

35. Yasar HY, Demirpence M, Colak A, et al. Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism. Arch Endocrinol Metab 2019; 63: 16–21.

36. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977–985.

37. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687–4694.

38. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821–1830.

39. Gong N, Gao C, Chen X, et al. Adipokine expression and endothelial function in subclinical hypothyroidism rats. Endocr Connect 2018; 7: 295–304.

40. Europemp. Anotace. (cit. 2018–09–17) Dostupné z www: . Li Y, Chang J, Jiang T, et al. Serum level of chemerin and bone mineral density in patients with Graves disease. J Cent South Univ 2017; 42(8): e947-e952. Dostupné z DOI:

41. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. PPAR Research 2009: 345320.

42. Wahrenberg H, Wennlund A, Hoffstedt J. Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves’ hyperthyroidism. Eur J Endocrinol 2002; 146: 607–611.

43. Rosc D, Zastawna E, Drewniak W, et al. Plasminogen activators (tissue type t-PA, urokinase type u-PA) and plasminogen activator inhibitor type 1 (PAI-1) in Graves disease. Med Sci Monit 1998; 4: 975–978.

44. Davies PH, Black EG, Sheppard MC, et al. Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness. CLin Endocrinol (Oxf) 1996; 44: 199–205.

45. Bartalena L, Brogioni S, Grasso L, et al. Interleukin-6: a marker of thyroid destructive process? J Clin Endocrinol Metab. 1994; 79: 1424–1427.

46. Ambati S, Kim HK, Yang KY, et al. Effects of leptin on apoptosis and adipogenesis in 3T3-L1 adipocytes. Biochem Pharmacol 2007; 73: 378–384.

47. Torgerson JS, Carlsson B, Stenlöf F, et al. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J Clin Endocrinol Metab 1999; 84: 4197–4203.

48. Näslund E, Andersson I, Degerblad M, et al. Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting obese men. J Intern Med 2000; 248: 299–308.

49. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. Arch Dis Child 2002; 87: 320–323.

50. Yoshida T, Momotani M, Hayashi M, et al. Serum leptin concentrations in patients with thyroid disorders. Clin Endocrinol (Oxf) 1998; 48: 299–302.

51. Nakamura T, Nagasaka S, Ishikawa S, et al. Association of hyperthyroidism with serum leptin levels. Metabolism 2000; 49: 1285–1288.

52. Escobar-Morreale HF, Escobar del Rey F, Morreale de Escobar G. Thyroid hormones influence serum leptin concentrations in the rat. Endocrinology 1997; 138: 4485–4488.

53. Zabrocka L, Klimek J, Swierczynski J. Evidence that triiodothyronine decreases rat serum leptin concentration by down-regulation of leptin gene expression in white adipose tissue. Life Sci 2006; 79: 1114–1120.

54. Mantzoros CS, Ozata M, Negrao AB, et al. Synchronicity of frequntly sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: Evidence for possible partial TSH regulation by leptin in humans. J CLin Endocrinol Metab 2001; 86: 3284–3291.

55. Pinkney JH, Goodrick SJ, Katz J, et al. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol (Oxf). 1998; 49: 583–588.

56. Valcavi R, Zini M, Peino R, et al. Influence of thyroid status on serum immunoreactive leptin levels. J Clin Endocrinol Metab. 1997; 82: 1632–1634.

57. Corbetta S, Englaro P, Giambona S, et al. Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur J Endocrinol 1997; 137: 659–663.

58. Leonhardt U. Serum leptin levels in hypo- and hyperthyroidism. Eur J Endocrinol 1998; 157: 75–79.

59. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. Eur J Clin Invest 2011; 41: 1202–1209.

60. Guzel S, Seven A, Guzel EC, et al. Visfatin, leptin, and TNF-α: Interrelated adipokines in insulin-resistant clinical and subclinical hypothyroidism. Endocr Res 2013; 38. Dostupné z DOI:

61. Bétry C, et al. Increased TSH in obesity: Evidence for a BMI-independent association with leptin. Diabetes Metab 2015; 41: 248–251.

62. Mazaki-Tovi M, Feuermann Y, Segev G, et al. Increased serum leptin and insulin concentrations in canine hypothyroidism. Vet J 2010; 18: 109–114.

63. Macek Jílková Z, Pavelka S, Flachs P, et al. Modulation of type I iodothyronine 5’-deiodinase activity in white adipose tissue by nutrition: possible involvement of leptin. Physiol Res 2010; 59: 61–69.

64. Luvizotto RA, Conde SA, Síbio MT, et al. Administration of physiologic levels of triiodothyronine increases leptin expression in calorie-restricted obese rats, but does not influence weight loss. Metabolism 2010; 59: 1–6.

65. Journals.Anotace. (cit. 2018–09–17) Dostupné z www: . de Oliveira M, Luvizotto A, Olimpio RM, et al. Triiodothyronine increases mRNA and protein leptin levels in short time in 3T3- L1 adipocytes by PI3K pathway activation. PLoS One 2013; 8(9). Dostupné z DOI:

66. Eray E, Sari F, Ozdem S, et al. Relationship between thyroid volume and iodine, leptin, and adiponectin in obese women before and after weight loss. Med Princ Pract 2011; 20: 43–46.

67. Gao CX, Yang B, Guo Q, et al. High thyroid-stimulating hormone level is associated with the risk of developing atherosclerosis in subclinical hypothyroidism. Horm Metab Res 2015; 47: 220–224.

68. Cerit ET, Akturk M, Altinova AE, et al. Evaluation of body composition changes, epicardial adipose tissue, and serum omentin-1 levels in overt hypothyroidism. Endocrine 2015; 49: 196–203.

69. Stumvoll M, Häring H. Resistin and adiponectin – of mice and men. Obesity 2002; 10: 1197–1199.

70. Nogueiras R, Guailillo O, Caminos JE, et al. Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 2003; 11: 408–414.

71. Krassas G E, Pontikides N, Loustis K, et al. Resistin levels in hyperthyroid patients before and after restoration of thyroid function: relationship with body weight and body composition. Eur J Endocrinol 2005; 153: 217–221.

72. El Gawad SS, El Kenawy F, Mousa AA, et al. Plasma levels of resistin and ghrelin before and after treatment in patients with hyperthyroidism. Endocr Pract 2012; 18: 376–381.

73. Krassas GE, Pontikides N, Loustis K, et al. Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. J Endocrinol Invest 2006; 29: 606–612.

74. Ziora, KT, Oswiecimska JM, Swietochowska E, et al. Assessment of serum levels resistin in girls with anorexia nervosa. Part II. Relationships between serum levels of resistin and thyroid, adrenal and gonadal hormones. Neuro Endocrinol Lett 2011; 32: 697–703.

75. Murphy K, Travers P, Walport M. Janeway’s Immunobiology. 7th ed. Garland Science: New York (USA) 2008.

76. Díez JJ, Hernanz A, Medina S, et al. Serum concentrations of tumor necrosis factor-alpha and soluble tumor necrosis factor-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 2002; 57: 515–521.

77. Blüher M. Vaspin in obesity and diabetes: patophysiological and clinical significance. Endocrine 2012; 41: 176–182.

78. Stančík M, Mokáň M, Sádová I, et al. Úloha vaspínu v patogenéze koronárnej choroby srdca. Vnitř Lék 2015; 61: (Suppl. 2): 14–19.

79. Gonzalez CR, Caminos JE, Vazquez MJ, et al. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. Journal of Physiology. 2009; 587: 3741–3750.

80. Handisurya A, Riedl M, Vila G, et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obesity Surgery 2010; 20: 198–203.

81. Cinar N, Gülçelik NE, Aydín K, et al. Serum vaspin levels in hypothyroid patients. Eur J Endocrinol. 2011; 165: 563–569.

82. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol and Cell Biol 1994; 14: 1431–1437.

83. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748–1758.

84. Tanaka M, Nozaki M, Fukuhara A, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 2007; 359: 194–201.

85. Chu CH, Lee JK, Wang MC, et al. Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism. Metabolism 2008; 57: 1380–1383.

86. Han J, Zhang TO, Xiao WH, et al. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chin Med J 2012; 125: 874–881.

87. MacLaren R, Cui W, Cianflone K Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 2007; 9: 490–497.

88. Ozkaya M, Sahin M, Cakal E, et al. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Invest 2009; 32: 435–439.

89. Caixàs A, Tirado R, Vendrell J, et al. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71: 733–738.

90. Imrich R Metabolické dôsledky chronického zápalu. In: Úvod do imunológie a patogenéza vybraných autoimunitných ochorení. Bratislava: Vydavateľstvo UK 2016, 33–34.

91. Smékal A, Václavík J, Stejskal D, et al. Je u mladých pacientů s infarktem myokardu možné vyšetřovat expresi adipokinů v leukocytech periferní krve? In: XXXII. dny mladých internistů. Vnitř Lék 2013; 59: 1P1–1P36.